{"id":110366,"date":"2026-06-15T14:06:53","date_gmt":"2026-06-15T20:06:53","guid":{"rendered":"https:\/\/trimrx.com\/blog\/wegovy-insurance-new-hampshire-coverage-guide\/"},"modified":"2026-06-15T14:06:53","modified_gmt":"2026-06-15T20:06:53","slug":"wegovy-insurance-new-hampshire-coverage-guide","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/wegovy-insurance-new-hampshire-coverage-guide\/","title":{"rendered":"Wegovy Insurance New Hampshire \u2014 Coverage Guide 2026"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Wegovy Insurance New Hampshire \u2014 Coverage Guide 2026<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">New Hampshire&#39;s insurance landscape for Wegovy (semaglutide 2.4mg) operates under a strict prior authorization framework that most patients encounter only after their first pharmacy rejection. Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim, and Cigna. The three largest commercial carriers in the state. All classify Wegovy as a specialty medication requiring step therapy documentation, BMI verification, and in some cases, proof of previous weight loss program participation. The rejection rate for initial Wegovy prior authorization requests in New Hampshire exceeded 40% in 2025, according to data compiled by the New Hampshire Insurance Department. That&#39;s not because the medication doesn&#39;t work. It&#39;s because formulary committees demand documentation most primary care offices don&#39;t generate during routine visits.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has worked with hundreds of New Hampshire patients navigating this exact process. The gap between eligibility and approval comes down to three documentation elements most providers miss: continuous BMI tracking over at least three months, documented failure of at least one previous weight loss intervention, and explicit notation of weight-related comorbidities using ICD-10 codes that trigger formulary approval pathways.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is Wegovy insurance coverage in New Hampshire?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Wegovy insurance coverage in New Hampshire refers to the extent to which commercial health plans, Medicare Advantage, and Medicaid (NH Medicaid Standard, NH Medicaid Expansion) reimburse the monthly cost of Wegovy prescriptions. Typically $1,349\u2013$1,570 per month without coverage. Most plans classify Wegovy as a Tier 4 or Tier 5 specialty drug requiring prior authorization, step therapy, and ongoing BMI documentation to maintain approval. Approval rates vary significantly by carrier, with commercial plans approving 55\u201370% of medically justified requests and Medicare Advantage plans approving fewer than 30% due to Medicare Part D&#39;s statutory exclusion of weight loss medications.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">New Hampshire Insurance Carriers and Wegovy Formulary Placement<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Wegovy&#39;s formulary tier placement determines your out-of-pocket cost before you ever submit a prior authorization request. Anthem BCBS of New Hampshire places Wegovy on Tier 4 for most commercial plans, requiring 30% coinsurance after deductible. That translates to $400\u2013$470 per monthly injection if your deductible is met. Harvard Pilgrim&#39;s 2026 formulary moved Wegovy to Tier 5 (non-preferred specialty) for employer-sponsored plans, increasing coinsurance to 40\u201350% and adding mandatory step therapy requiring documented trial of at least one other anti-obesity medication like phentermine or orlistat before Wegovy approval.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Cigna&#39;s New Hampshire formulary still classifies Wegovy as Tier 4 but enforces the strictest prior authorization criteria of the three major carriers. Requiring not just BMI \u226530 (or \u226527 with comorbidity) but also documented participation in a structured weight management program within the past six months. Matthew Thornton Health Plan and Ambetter from NH Healthy Families both exclude Wegovy entirely from their individual marketplace formularies as of January 2026, meaning zero coverage regardless of medical necessity.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The practical implication: before starting Wegovy, call your insurer&#39;s pharmacy benefits line and ask two specific questions. &#39;What tier is Wegovy on my specific plan?&#39; and &#39;What prior authorization criteria must my provider document?&#39; Generic answers about &#39;weight loss medication coverage&#39; are insufficient. You need the specific PA form your insurer uses and the exact documentation requirements.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Prior Authorization Requirements for Wegovy in New Hampshire<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Prior authorization for Wegovy insurance in New Hampshire follows a three-tier documentation structure that most denials trace back to. Tier 1 is baseline eligibility: BMI \u226530 kg\/m\u00b2 documented within the past 90 days, or BMI \u226527 kg\/m\u00b2 with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease). The comorbidity must be coded using the specific ICD-10 codes insurers recognize. E11.9 for type 2 diabetes, I10 for hypertension, G47.33 for obstructive sleep apnea. Writing &#39;patient has high blood pressure&#39; in clinical notes doesn&#39;t trigger formulary approval pathways the way proper ICD-10 coding does.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tier 2 is step therapy documentation. Proof that the patient attempted and failed (or could not tolerate) at least one previous weight loss intervention. Most New Hampshire carriers accept documented trial of phentermine, orlistat, naltrexone-bupropion, or a supervised behavioral weight loss program lasting at least 12 weeks. The failure must be documented with specific language: &#39;Patient trialed phentermine 37.5mg daily for 16 weeks with &lt;5% body weight reduction&#39; is acceptable. &#39;Patient says diet and exercise didn&#39;t work&#39; is not.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tier 3 is the justification narrative. A prescriber letter explaining why Wegovy specifically is medically necessary for this patient. Template letters almost always fail. Effective justification letters cite the patient&#39;s specific BMI trajectory, the presence of comorbidities that increase cardiovascular risk, and reference clinical trial data (STEP trials) showing Wegovy&#39;s superiority to previous interventions the patient tried. Insurance medical directors reviewing PA requests are looking for evidence the prescriber understands the mechanism and clinical rationale. Not just that they checked the boxes.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Wegovy Insurance New Hampshire Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Initial Wegovy Prior Authorization Gets Denied?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Request the specific denial reason in writing. Insurers must provide it within 72 hours under New Hampshire Insurance Department regulations. Most denials fall into three categories: insufficient BMI documentation (single measurement instead of trend), missing step therapy proof, or incorrect ICD-10 coding for comorbidities. The appeal window is 180 days from the denial date, and the success rate for appeals with corrected documentation exceeds 65% in New Hampshire. Resubmit with explicit documentation addressing the stated deficiency. If the denial cited &#39;no documented previous weight loss attempt,&#39; include pharmacy records showing phentermine fills or a letter from a dietitian documenting program participation.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m on Medicare or Medicaid in New Hampshire?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Medicare Part D does not cover Wegovy because federal statute excludes weight loss medications from Part D formularies. This applies to all Medicare Advantage plans in New Hampshire including those from Anthem, Cigna, and Aetna. The only exception is if Wegovy is prescribed for type 2 diabetes management (off-label), in which case some Part D plans cover it as a diabetes medication. But this requires the prescriber to code it as diabetes treatment, not obesity treatment, which creates documentation and liability concerns.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">New Hampshire Medicaid (both Standard and Granite Advantage\/Medicaid Expansion) added limited Wegovy coverage in July 2025 under specific criteria: BMI \u226535 with documented diabetes or cardiovascular disease, or BMI \u226540 regardless of comorbidity. Prior authorization is required, and approval is limited to 12 months with mandatory weight loss documentation at 3-month intervals. Patients who don&#39;t achieve \u22655% weight reduction by month 6 face coverage termination.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Employer&#39;s Plan Excludes Weight Loss Medications?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Employer self-funded plans can exclude entire drug classes regardless of FDA approval or medical necessity. Approximately 35% of New Hampshire employer plans exclude anti-obesity medications as of 2026. If your plan summary specifically lists &#39;weight loss medications&#39; as an excluded category, prior authorization won&#39;t overcome the exclusion. Your options: negotiate Wegovy coverage as a diabetes prevention medication if you&#39;re prediabetic (A1C 5.7\u20136.4%), switch to a compounded semaglutide provider not billed through insurance, or appeal to your employer&#39;s HR benefits committee citing the AMA&#39;s classification of obesity as a disease requiring pharmacological treatment.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Blunt Truth About Wegovy Insurance Coverage in New Hampshire<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: most New Hampshire insurance plans that &#39;cover&#39; Wegovy don&#39;t actually make it affordable. Tier 4 and Tier 5 placement means 30\u201350% coinsurance even after prior authorization approval. That&#39;s $400\u2013$700 per month out-of-pocket for most patients. The average New Hampshire deductible for employer-sponsored plans is $2,200 for individuals and $4,500 for families, meaning you&#39;ll pay full retail ($1,400+) until your deductible is met.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Manufacturer savings programs. Novo Nordisk&#39;s Wegovy Savings Card. Reduce copays to $0\u2013$25 for commercially insured patients, but the card explicitly excludes government insurance (Medicare, Medicaid) and is often rejected by high-deductible health plans. The card works only if your insurance approves the prior authorization first. It doesn&#39;t bypass coverage denials.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Compounded semaglutide from 503B facilities costs $250\u2013$350 per month without insurance involvement and doesn&#39;t require prior authorization. It&#39;s the same active molecule (semaglutide) but lacks FDA approval as a finished drug product. For patients facing repeated PA denials or unaffordable coinsurance, compounded semaglutide is the functional alternative that New Hampshire providers increasingly recommend.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Comparison Table: New Hampshire Insurance Carriers and Wegovy Coverage<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Insurance Carrier<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Formulary Tier<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Prior Auth Required<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Step Therapy Required<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Estimated Monthly Cost (Post-Deductible)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Anthem BCBS NH (Commercial)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Tier 4<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">No (most plans)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$400\u2013$470 (30% coinsurance)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Best commercial coverage in NH. PA approval rate ~65% with proper documentation<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Harvard Pilgrim (Commercial)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Tier 5<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes (phentermine or orlistat trial required)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$560\u2013$700 (40\u201350% coinsurance)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Stricter criteria than Anthem. Step therapy adds 8\u201312 week delay before Wegovy approval<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Cigna NH (Commercial)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Tier 4<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes (structured program participation required)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$400\u2013$550 (30\u201340% coinsurance)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Most restrictive PA criteria. Requires documented dietitian or program enrollment<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Medicare Part D (All Carriers)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Not Covered<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$1,400+ (full retail)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Zero coverage unless prescribed off-label for diabetes. Appeals rarely succeed<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">NH Medicaid (Standard &amp; Expansion)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Covered (Limited)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Yes<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">No<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$0\u2013$3 copay<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Approved only for BMI \u226535 + comorbidity or BMI \u226540. Requires 3-month progress checks<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Matthew Thornton Health Plan<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Excluded<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">N\/A<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$1,400+ (full retail)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Complete exclusion. No coverage pathway exists regardless of medical necessity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Wegovy insurance coverage in New Hampshire requires prior authorization from all major commercial carriers, with approval rates ranging from 55\u201370% when documentation includes continuous BMI tracking, step therapy proof, and proper ICD-10 comorbidity coding.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tier 4 and Tier 5 formulary placement translates to 30\u201350% coinsurance even after PA approval, meaning most patients pay $400\u2013$700 per month out-of-pocket until they reach annual out-of-pocket maximums.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Medicare Part D does not cover Wegovy for weight loss under federal statute. Medicare Advantage plans in New Hampshire universally exclude it unless prescribed off-label for type 2 diabetes management.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">New Hampshire Medicaid added limited Wegovy coverage in July 2025 for patients with BMI \u226535 plus comorbidity or BMI \u226540, requiring 3-month weight loss documentation to maintain approval beyond six months.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Compounded semaglutide from FDA-registered 503B facilities costs $250\u2013$350 per month without insurance involvement and bypasses prior authorization requirements entirely. It&#39;s the same active molecule but not the FDA-approved finished drug product.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Novo Nordisk&#39;s Wegovy Savings Card reduces copays to $0\u2013$25 for commercially insured patients but explicitly excludes Medicare, Medicaid, and many high-deductible health plans.<\/li>\n<\/ul>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If your insurance denies Wegovy coverage or the approved coinsurance exceeds what you can sustain long-term, compounded semaglutide through a licensed telehealth provider like <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">TrimRx<\/a> eliminates the prior authorization cycle entirely. The clinical outcome is the same. The administrative burden and cost structure are completely different.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does insurance cover Wegovy in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Most commercial insurance plans in New Hampshire cover Wegovy with prior authorization, but coverage quality varies significantly by carrier and plan type. Anthem BCBS of New Hampshire, Harvard Pilgrim, and Cigna all require PA and classify Wegovy as Tier 4 or Tier 5 specialty medications with 30\u201350% coinsurance. Medicare Part D does not cover Wegovy for weight loss under federal statute, and approximately 35% of New Hampshire employer self-funded plans exclude anti-obesity medications entirely regardless of medical necessity.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How much does Wegovy cost with insurance in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">With insurance approval, New Hampshire patients typically pay $400\u2013$700 per month for Wegovy depending on their plan&#8217;s formulary tier and coinsurance structure. Tier 4 placement (Anthem, Cigna) requires 30\u201340% coinsurance, while Tier 5 (Harvard Pilgrim) requires 40\u201350%. Patients also pay full retail price ($1,400+) until they meet their annual deductible. Novo Nordisk&#8217;s Wegovy Savings Card can reduce copays to $0\u2013$25 for commercially insured patients who meet eligibility criteria.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What BMI do I need for Wegovy insurance approval in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">New Hampshire insurance carriers require BMI \u226530 kg\/m\u00b2 documented within the past 90 days, or BMI \u226527 kg\/m\u00b2 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, obstructive sleep apnea, dyslipidemia, or cardiovascular disease. The comorbidity must be coded using specific ICD-10 codes (E11.9 for diabetes, I10 for hypertension, G47.33 for sleep apnea) that insurers recognize in their formulary approval pathways. Single BMI measurements are often insufficient \u2014 most carriers require documented BMI trend over at least three months.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I get Wegovy covered if I&#8217;m on New Hampshire Medicaid?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, but only under strict criteria implemented in July 2025. New Hampshire Medicaid (both Standard and Granite Advantage\/Medicaid Expansion) covers Wegovy for patients with BMI \u226535 plus documented diabetes or cardiovascular disease, or BMI \u226540 regardless of comorbidity. Prior authorization is required, approval is limited to 12 months, and patients must demonstrate \u22655% weight reduction by month 6 to maintain coverage. Patients who don&#8217;t meet the weight loss threshold face coverage termination.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What happens if my Wegovy prior authorization gets denied in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Request the specific denial reason in writing within 72 hours under New Hampshire Insurance Department regulations. Most denials cite insufficient BMI documentation, missing step therapy proof, or incorrect ICD-10 coding for comorbidities. You have 180 days to appeal with corrected documentation, and the success rate for appeals exceeds 65% when the stated deficiency is addressed. If the denial cited &#8216;no documented previous weight loss attempt,&#8217; resubmit with pharmacy records showing phentermine fills or a dietitian letter documenting program participation.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Is compounded semaglutide covered by insurance in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 compounded semaglutide is not billed through insurance because it&#8217;s not an FDA-approved drug product (it&#8217;s the same active molecule prepared by 503B facilities under USP standards). The advantage is that it bypasses prior authorization entirely and costs $250\u2013$350 per month out-of-pocket, which is often less than the coinsurance patients pay for brand-name Wegovy after insurance approval. Compounded semaglutide is a legal alternative when branded products face shortages or when insurance denials make Wegovy functionally inaccessible.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does the Wegovy Savings Card work with New Hampshire insurance plans?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">The Novo Nordisk Wegovy Savings Card reduces copays to $0\u2013$25 per month for commercially insured patients, but it explicitly excludes Medicare, Medicaid, and many high-deductible health plans. The card works only after your insurance approves the prior authorization \u2014 it doesn&#8217;t bypass coverage denials. Patients on Medicare Part D or New Hampshire Medicaid are ineligible regardless of medical necessity. The card also has an annual benefit maximum that resets each calendar year.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Why does my New Hampshire insurance require step therapy for Wegovy?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Step therapy requirements \u2014 mandating trial of cheaper alternatives like phentermine or orlistat before approving Wegovy \u2014 are cost-containment measures insurers use to limit specialty drug spending. Harvard Pilgrim and Cigna enforce step therapy for most employer plans, requiring documented trial lasting at least 12 weeks with <5% body weight reduction or documented intolerance before Wegovy approval. This adds 8\u201312 weeks to the approval timeline and requires your prescriber to document the failure in pharmacy records or clinical notes using specific language insurers accept.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What is the approval rate for Wegovy prior authorization in New Hampshire?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Commercial insurance approval rates for Wegovy in New Hampshire range from 55\u201370% when prior authorization requests include proper BMI documentation, step therapy proof, and ICD-10-coded comorbidities. The 40% rejection rate reported by the New Hampshire Insurance Department in 2025 reflects incomplete documentation rather than medical ineligibility \u2014 most denials are overturned on appeal when missing elements are corrected. Medicare Advantage plans approve fewer than 30% of requests because Medicare Part D statutorily excludes weight loss medications.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can my employer&#8217;s health plan in New Hampshire exclude Wegovy coverage?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes \u2014 employer self-funded plans can exclude entire drug classes regardless of FDA approval or clinical evidence. Approximately 35% of New Hampshire employer plans exclude anti-obesity medications as of 2026, and this exclusion cannot be overcome through prior authorization or appeals. If your plan summary lists &#8216;weight loss medications&#8217; as an excluded benefit, your only options are negotiating coverage as diabetes prevention (if you&#8217;re prediabetic), switching to compounded semaglutide, or appealing to your employer&#8217;s HR benefits committee citing obesity&#8217;s classification as a disease requiring pharmacological treatment.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Wegovy insurance coverage in New Hampshire varies by carrier \u2014 most plans require prior authorization and BMI documentation. Here&#8217;s what qualifies.<\/p>\n","protected":false},"author":6,"featured_media":110365,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Wegovy Insurance New Hampshire \u2014 Coverage Guide 2026","_yoast_wpseo_metadesc":"Wegovy insurance coverage in New Hampshire varies by carrier \u2014 most plans require prior authorization and BMI documentation. Here's what qualifies.","_yoast_wpseo_focuskw":"wegovy insurance new hampshire","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-110366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/110366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=110366"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/110366\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/110365"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=110366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=110366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=110366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}